TARS
Tarsus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$90.78
+9.10%Aug 26, 2026, 14:42 UTC
The U.S. Federal Trade Commission granted early termination of the waiting period under the HSR Act for Tarsus's acquisition of Alkeus.
Source:Aug 6, 2026, 11:03 UTC
Tarsus reported second quarter 2026 financial results, with XDEMVY net product sales of $173.9 million, up more than 69% year-over-year.
Aug 6, 2026, 11:02 UTC
Tarsus Pharmaceuticals announced an oversubscribed $125.0 million private placement equity financing with qualified institutional buyers and accredited investors.
Source:Aug 6, 2026, 11:01 UTC
Tarsus Pharmaceuticals agreed to acquire Alkeus Pharmaceuticals, adding the Phase 3 oral investigational drug gildeuretinol (ALK-001) for Stargardt disease to its pipeline.
Jul 13, 2026, 20:05 UTC
Tarsus Pharmaceuticals announced the departure of Chief Commercial Officer Aziz Mottiwala and the appointment of Neera Clase as Interim Chief Commercial Officer.
Source:Jul 11, 2026, 14:02 UTC
Tarsus Pharmaceuticals acquired iRenix Medical, Inc., adding IRX-101 to its pipeline and entering the retina market.
Source:Jul 8, 2026, 20:05 UTC
Tarsus acquired iRenix Medical and its late-stage asset IRX-101.